US · Technology · Software - Application
EPS came in at 0.03 against a street estimate of 0.03 — a beat of 0.0%.
Analysts rate Materialise NV a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $8.80.
MIXED Materialise delivered 2% revenue growth, strong Medical and series-production momentum, but Software declined and higher R&D limited quarterly margins. Q3 FY26 Phits Dynaprint volumes tripled sequentially after North American expansion; U.K. and Ireland volumes doubled. The Superhumans Center agreement supports care in Ukraine. Analysts focused on the manufacturing mix, growth drivers, and Software’s weak performance. Management highlighted balanced series production and prototyping, diversified demand, and longer CO-AM sales cycles. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Disciplined Growth Investors Inc | 3.46% |
| Rock Point Advisors, LLC | 1.72% |
| Archon Capital Management LLC | 1.33% |
| King Luther Capital Management Corp | 1.09% |
| Acadian Asset Management LLC | 1.05% |
| Arrowstreet Capital Limited Partnership | 0.83% |
| ARK Investment Management LLC | 0.73% |
| Renaissance Technologies Corp | 0.51% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Materialise NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.